Cost-effectiveness of abatacept, tocilizumab and TNF-inhibitors compared with rituximab as second-line biologic drug in rheumatoid arthritis

OBJECTIVES: The objective of this study was to evaluate the cost-effectiveness of abatacept, tocilizumab, and tumor necrosis factor (TNF) inhibitors as compared with rituximab in Finnish rheumatoid arthritis patients, who have previously been treated with TNF inhibitors. METHODS: A patient-level sim...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:PLoS One
Glavni autori: Huoponen, Saara, Aaltonen, Kalle J., Viikinkoski, Jaana, Rutanen, Jarno, Relas, Heikki, Taimen, Kirsi, Puolakka, Kari, Nordström, Dan, Blom, Marja
Format: Artigo
Jezik:Inglês
Izdano: Public Library of Science 2019
Teme:
Research Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6656352/
https://ncbi.nlm.nih.gov/pubmed/31339961
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0220142
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items